Novartis Pulls EU Marketing Application For Xiidra
End Of Road For EU Marketing Plans For Dry Eye Drug?
Novartis recognized it would not be able to answer objections relating to its EU marketing application for the dry eye drug, Xiidra (lifitegrast), and so it has withdrawn the application. The company last year paid upwards of $3bn for the drug, which is already marketed in the US and other markets.
